Sehgal A, Gupta I, Sehgal R, Ganguly N K
Department of Obstetrics and Gynaecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Acta Virol. 1992 Aug;36(4):359-66.
The efficacy of hepatitis B virus (HBV) vaccine alone (group I) or in combination with hepatitis B immunoglobulin (HBIG) (group II) for prevention of perinatal transmission of the virus was assessed in 21 and 24 neonates, respectively. 58 infants who could not be vaccinated constituted the control group. It was observed that in the unvaccinated group approximately 70% of the infants became infected. In both the vaccinated groups, the seroconversion and seroprotection rates (anti-HBs > or = 10 IU/1) were almost similar at 6 months of follow up, but, at 12 months, infants given HBIG and vaccine showed better seroprotection rate (85%) than those given vaccine alone (58.8%). Immune response to the vaccine was also better in both the groups if the mothers were anti-HBe positive. Despite immunization, 14.2% and 25% infants in group I and II, respectively, became chronic carriers if their mothers were HBeAG positive.
分别在21名和24名新生儿中评估了单独使用乙肝病毒（HBV）疫苗（I组）或联合使用乙肝免疫球蛋白（HBIG）（II组）预防围产期病毒传播的效果。58名未接种疫苗的婴儿组成了对照组。观察到在未接种疫苗的组中，约70%的婴儿被感染。在两个接种疫苗的组中，随访6个月时血清转化率和血清保护率（抗-HBs>或=10 IU/1）几乎相似，但在12个月时，接受HBIG和疫苗的婴儿血清保护率（85%）高于仅接受疫苗的婴儿（58.8%）。如果母亲抗-HBe阳性，两组对疫苗的免疫反应也更好。尽管进行了免疫接种，但如果母亲HBeAg阳性，I组和II组分别有14.2%和25%的婴儿成为慢性携带者。
